4512 WAKAMOTO PHARMACEUTICAL CO.,LTD. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4512

TSE Standard

WAKAMOTO PHARMACEUTICAL CO.,LTD.

282

JPY

(+0.71%)

Dec 5, 3:30 pm JST

1.82

USD

Dec 5, 1:30 am EST

Result

PTS

outside of trading hours

ー

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2022	8,383	-13	72	238	6.9	0	May 16, 2022	J-GAAP
Mar, 2023	8,660	141	242	138	4.0	3	May 15, 2023	J-GAAP
Mar, 2024	7,738	-195	-161	108	3.1	3	May 15, 2024	J-GAAP
Mar, 2025	7,789	-457	-409	64	1.9	3	May 15, 2025	J-GAAP
Mar, 2026 Guidance	10,000	200	250	200	5.8	3	May 15, 2025	J-GAAP
YoY	+28.4%	－	－	+212.5%	+211.4%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2021	May 27, 2020	10,100	10	40	240	－	J-GAAP
-	Nov 4, 2020	9,400	-600	-500	-600	0	J-GAAP
Results	May 14, 2021	8,895	-754	-604	-601	0	J-GAAP
Mar, 2022	May 14, 2021	Available in future release
	Aug 4, 2021
	Mar 25, 2022
	May 6, 2022
Results	May 16, 2022
Mar, 2023	May 16, 2022
	Mar 27, 2023
	Apr 27, 2023
Results	May 15, 2023
Mar, 2024	May 15, 2023
	Feb 5, 2024
	Mar 8, 2024
	Mar 22, 2024
	Apr 26, 2024
Results	May 15, 2024
Mar, 2025	May 15, 2024
	Mar 25, 2025
	Apr 25, 2025
Results	May 15, 2025
Mar, 2026	May 15, 2025	10,000	200	250	200	3	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2001	10,707	+7.1	Available in future release
Mar, 2002	9,732	-9.1
Mar, 2003	10,077	+3.5
Mar, 2004	10,048	-0.3
Mar, 2005	10,031	-0.2
Mar, 2006	10,185	+1.5
Mar, 2007	10,327	+1.4
Mar, 2008	10,169	-1.5
Mar, 2009	10,080	-0.9
Mar, 2010	9,776	-3.0
Mar, 2011	9,669	-1.1
Mar, 2012	9,432	-2.5
Mar, 2013	9,927	+5.2
Mar, 2014	10,328	+4.0
Mar, 2015	10,736	+4.0
Mar, 2016	11,183	+4.2
Mar, 2017	10,830	-3.2
Mar, 2018	10,900	+0.6
Mar, 2019	10,739	-1.5
Mar, 2020	10,916	+1.6
Mar, 2021	8,895	-18.5
Mar, 2022	8,383	-5.8
Mar, 2023	8,660	+3.3
Mar, 2024	7,738	-10.6
Mar, 2025	7,789	+0.7
Mar, 2026 Guidance	10,000	+28.4	200	－	250	－	5.8	+205.3

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Mar, 2024	7,738	-195	-2.5	0.90	0.69	0.50	3.1
Mar, 2025	7,789	-457	-5.9	0.54	0.42	0.51	1.9
Mar, 2026 Guidance	10,000	200	2.00	1.73	1.34	0.67	5.8

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	11,183	1,102	1,294	844	24.3
Fiscal Year	Mar, 2016	Mar, 1988	Mar, 2001	Mar, 2014	Mar, 2014

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2022	4,641	226	269	159	4.6	3	May 15, 2023	J-GAAP
Oct - Mar, 2023	4,120	133	158	330	9.6	3	May 15, 2024	J-GAAP
Oct - Mar, 2024	3,978	-181	-153	205	5.9	3	May 15, 2025	J-GAAP
Oct - Mar, 2025 Guidance	5,618	395	425	334	9.6	3	Nov 6, 2025	J-GAAP
YoY	+41.2%	－	－	+62.9%	+62.2%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Mar, 2023	141	648	631	17	-1	3,879	24.69	J-GAAP
Mar, 2024	-195	-109	-107	-2	-104	3,664	23.76	J-GAAP
Mar, 2025	-457	-605	-592	-13	-103	2,954	19.69	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 2nd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Sep, 2023	3,618	-328	-319	-222	-6.4	ー	Nov 6, 2023	J-GAAP
Apr - Sep, 2024	3,811	-276	-256	-141	-4.1	ー	Nov 6, 2024	J-GAAP
Apr - Sep, 2025	4,382	-195	-175	-134	-3.9	ー	Nov 6, 2025	J-GAAP
YoY	+15.0%	+29.3%	+31.6%	+5.0%	+5.4%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2023	1,968	69	94	17	0.5	3.5	Feb 5, 2024	J-GAAP
Jan - Mar, 2024	2,152	64	64	313	9.1	3.0	May 15, 2024	J-GAAP
Apr - Jun, 2024	1,884	-89	-64	-11	-0.3	-4.7	Aug 2, 2024	J-GAAP
Jul - Sep, 2024	1,927	-187	-192	-130	-3.8	-9.7	Nov 6, 2024	J-GAAP
Oct - Dec, 2024	1,995	-65	-41	122	3.5	-3.3	Feb 5, 2025	J-GAAP
Jan - Mar, 2025	1,983	-116	-112	83	2.4	-5.8	May 15, 2025	J-GAAP
Apr - Jun, 2025	2,168	-143	-117	-108	-3.1	-6.6	Aug 5, 2025	J-GAAP
Jul - Sep, 2025	2,214	-52	-58	-26	-0.8	-2.3	Nov 6, 2025	J-GAAP
YoY	+14.9%	+72.2%	+69.8%	+80.0%	+80.1%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2020	2,394	-22.9	Available in future release
Jan - Mar, 2021	2,220	-8.6
Apr - Jun, 2021	1,965	-7.7
Jul - Sep, 2021	2,042	-5.1
Oct - Dec, 2021	2,259	-5.6
Jan - Mar, 2022	2,117	-4.6
Apr - Jun, 2022	2,023	+3.0
Jul - Sep, 2022	1,996	-2.3
Oct - Dec, 2022	2,248	-0.5
Jan - Mar, 2023	2,393	+13.0
Apr - Jun, 2023	1,860	-8.1
Jul - Sep, 2023	1,758	-11.9
Oct - Dec, 2023	1,968	-12.5
Jan - Mar, 2024	2,152	-10.1
Apr - Jun, 2024	1,884	+1.3
Jul - Sep, 2024	1,927	+9.6
Oct - Dec, 2024	1,995	+1.4
Jan - Mar, 2025	1,983	-7.9
Apr - Jun, 2025	2,168	+15.1
Jul - Sep, 2025	2,214	+14.9	-52	+72.2	-58	+69.8	-0.8	+78.9

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	3,105	381	481	602	17.3
Fiscal Year	Dec, 2019	Dec, 2014	Dec, 2007	Mar, 2014	Mar, 2014

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Mar, 2023	343.06	75.8	15,711	11,906	4,706	0.01	May 15, 2023	J-GAAP
Mar, 2024	346.50	78.0	15,421	12,026	4,711	0.01	May 15, 2024	J-GAAP
Mar, 2025	334.53	77.4	15,002	11,610	4,671	0.01	May 15, 2025	J-GAAP
Apr - Sep, 2025	333.89	77.9	14,877	11,588	4,433	0.01	Nov 6, 2025	J-GAAP

WAKAMOTO PHARMACEUTICAL CO.,LTD.(4512) Financial Results